MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models
Overview
Chemistry
Molecular Biology
Authors
Affiliations
The transcription factor CEBPA is a master regulator of liver homeostasis, myeloid cell differentiation and is downregulated in several oncogenic diseases. MTL-CEBPA is a small activating RNA drug which upregulates gene expression of CEBPA for treatment of hepatocellular carcinoma (HCC). We investigate whether MTL-CEBPA has immune modulatory effects by combining MTL-CEBPA with an anti-PD-1 checkpoint inhibitor (CPI) and/or radiofrequency ablation (RFA) in two preclinical models. First, mice with two flanks of HCC tumors (BNL) were treated with combinations of RFA (right flank), anti-PD-1 or MTL-CEBPA. The reduction of the left flank tumors was most pronounced in the group treated with RFA+anti-PD1+MTL-CEBPA and 7/8 animals responded. This was the only group with a significant increase in CD8+ and CD49b+/CD45+ tumor infiltrating lymphocytes (TIL). Second, a combination of anti-PD-1+MTL-CEBPA was tested in a CT26 colon cancer model and this treatment significantly reduced tumor size, modulated the tumor immune microenvironment and increased TILs. These data suggest a clinical role for combination treatment with CPIs, RFA and MTL-CEBPA through synergistic priming of the immune tumor response, enabling RFA and CPIs to have a pronounced anti-tumor effect including activity in non-treated tumors in the case of RFA.
Liu M, Wang Y, Zhang Y, Hu D, Tang L, Zhou B Signal Transduct Target Ther. 2025; 10(1):73.
PMID: 40059188 PMC: 11891339. DOI: 10.1038/s41392-024-02112-8.
Meyiah A, Khan F, Alfaki D, Murshed K, Raza A, Elkord E Transl Oncol. 2025; 53:102307.
PMID: 39904281 PMC: 11846588. DOI: 10.1016/j.tranon.2025.102307.
Advancements in clinical RNA therapeutics: Present developments and prospective outlooks.
Saw P, Song E Cell Rep Med. 2024; 5(5):101555.
PMID: 38744276 PMC: 11148805. DOI: 10.1016/j.xcrm.2024.101555.
Bellone S, Jeong K, Halle M, Krakstad C, McNamara B, Greenman M Proc Natl Acad Sci U S A. 2024; 121(17):e2321898121.
PMID: 38625939 PMC: 11046577. DOI: 10.1073/pnas.2321898121.
Emerging roles of MITF as a crucial regulator of immunity.
Lee A, Lim J, Lim J Exp Mol Med. 2024; 56(2):311-318.
PMID: 38351314 PMC: 10907664. DOI: 10.1038/s12276-024-01175-5.